Targeting the anti-angiogenic factors of preeclampsia: soluble endoglin and sFlt1

靶向先兆子痫的抗血管生成因子：可溶性内皮糖蛋白和 sFlt1

• 批准号: nhmrc : 1062418
• 负责人: Dr Tu'Uhevaha Kaitu'U-Lino
• 金额: $ 29.81万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Career Development Fellowships
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-anti-angiogenic-endoglin-sflt1/454989
• 关键词: Targeting; anti; angiogenic; factors; preeclampsia

Preeclampsia is a severe disease of pregnancy - the placenta releases toxins in to mum's bloodstream that circulate her body and damage her organs. As there are no efficacious treatments, clinicians are forced to deliver babies irrespective of gestation. Although the two toxins of preeclampsia have been identified, little is known about their regulation. This project aims to elucidate the regulation of these toxins and design therapeutics that can prevent their release in the clinic.

先兆子痫是一种严重的妊娠疾病-胎盘释放毒素到妈妈的血液中，循环她的身体并损害她的器官。由于没有有效的治疗方法，临床医生被迫分娩婴儿，而不管怀孕与否。虽然已经确定了先兆子痫的两种毒素，但对它们的调节知之甚少。该项目旨在阐明这些毒素的调节，并设计可以防止其在临床中释放的治疗方法。